A Study of Novel Immune Modulating Biomarkers in Patients With Spondyloarthritis With Axial Involvement
NCT01969188 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70
Last updated 2025-12-24
Summary
Spondyloarthritis refers to a set of inflammatory disorders that mainly afflict the spine, joints and ligaments. A subtype of spondyloarthritis is Ankylosing Spondylitis - now known as axial spondyloarthropathy - which is characterized by inflammation of the joints in the spinal column, and the part of the back where the spine meets the pelvis. Another subtype of spondyloarthritis is Psoriatic Arthritis where patients often develop raised patches of reddened skin. The disease can advance to one of more joints in the body resulting in pain, swelling and stiffness. These forms of inflammatory arthritis can become chronic and over time can lead to pain, disability and deformity.
There is now evidence that patients with inflammatory arthritis that are diagnosed and treated earlier in the course of their symptoms may have better results. Yet although we know that early treatment is important, the investigators still don't know if there are factors that can predict how an individual patient's disease will progress over time in terms of losing mobility. The investigators also do not know the relationship between loosing mobility and the formation of bone around the spine and joints.
The investigators are doing this study because the investigators want to learn more about patients with these forms of arthritis - Ankylosing Spondylitis and Psoriatic Arthritis. The investigators want to learn more about the factors that can predict how their disease might progress over time and what their response to treatment might be. The investigators would also like to determine the proportion of patients with these types of symptoms and describe the best treatment strategies for them.
Conditions
- Spondyloarthritis
Sponsors & Collaborators
- collaborator INDUSTRY
-
Hospital for Special Surgery, New York
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-01-31
- Primary Completion
- 2025-12-18
- Completion
- 2025-12-18
Countries
- United States
Study Locations
More Related Trials
-
Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis
NCT00195819 ·Status: COMPLETED ·Phase: PHASE3
-
Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)
NCT00779935 ·Status: COMPLETED ·Phase: PHASE4
-
Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis
NCT01029847 ·Status: COMPLETED ·Phase: PHASE4
-
Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)
NCT00778869 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life
NCT02354105 ·Status: COMPLETED
-
Study of Adalimumab in Patients With Axial Spondyloarthritis
NCT00939003 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis
NCT00265083 ·Status: COMPLETED ·Phase: PHASE3
-
Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
NCT01087762 ·Status: COMPLETED ·Phase: PHASE3
-
Integral Single-cell Landscape of Immunological Hallmarks for Ankylosing Spondylitis
NCT06846021 ·Status: COMPLETED ·Phase: NA
-
A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting
NCT05094128 ·Status: RECRUITING
-
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
NCT04169373 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
NCT02757352 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of IL17 Inhibitor in Comparison With Anti-TNF in Patients With Ankylosing Spondylitis
NCT06642207 ·Status: RECRUITING
-
Analysis of Intestinal Microbiota as a Predictor of Response to Treatment of Spondyloarthritis With Biotherapy
NCT04899154 ·Status: RECRUITING ·Phase: NA
-
Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)
NCT01064856 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis
NCT00811499 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis
NCT02696798 ·Status: COMPLETED ·Phase: PHASE3
-
T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade
NCT01060098 ·Status: COMPLETED
-
A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis
NCT03215277 ·Status: COMPLETED ·Phase: PHASE2
-
Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes
NCT02469753 ·Status: COMPLETED ·Phase: PHASE3
-
Psoriatic Arthritis Research Collaborative: Biologic Sub-Study
NCT03378336 ·Status: COMPLETED
-
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
NCT00844805 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
NCT04436640 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis
NCT03622658 ·Status: COMPLETED ·Phase: PHASE2
-
Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis
NCT01590966 ·Status: COMPLETED ·Phase: PHASE3